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Abstract: Duchenne muscular dystrophy (DMD) is characterized by striated muscle weakness,
cardiomyopathy, and respiratory failure. Since oxidative stress is recognized as a secondary
pathology in DMD, the efficacy of antioxidant intervention, using the superoxide scavenger tempol,
was examined on functional and biochemical status of dystrophin-deficient diaphragm muscle.
Diaphragm muscle function was assessed, ex vivo, in adult male wild-type and dystrophin-deficient
mdx mice, with and without a 14-day antioxidant intervention. The enzymatic activities of
muscle citrate synthase, phosphofructokinase, and lactate dehydrogenase were assessed using
spectrophotometric assays. Dystrophic diaphragm displayed mechanical dysfunction and altered
biochemical status. Chronic tempol supplementation in the drinking water increased diaphragm
functional capacity and citrate synthase and lactate dehydrogenase enzymatic activities, restoring all
values to wild-type levels. Chronic supplementation with tempol recovers force-generating capacity
and metabolic enzyme activity in mdx diaphragm. These findings may have relevance in the search
for therapeutic strategies in neuromuscular disease.
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1. Introduction
Duchenne muscular dystrophy (DMD) is the most common form of inherited muscle disease in
childhood, with an estimated incidence of 1:3500 male births [1]. DMD is caused by a deficiency in the
protein dystrophin, which is a component of the dystrophin associated protein complex (DAPC) [2].
The DAPC has a structural role in linking the actin cytoskeleton to the extracellular matrix, thus
stabilizing the sarcolemma during muscle contraction and relaxation [3]. Dystrophin deficiency results
in destabilization of the DAPC, leading to muscle weakness and fragility, resulting in muscle damage,
fibrosis, and necrosis [4]. Inflammation is secondary to muscle damage in DMD, with attendant
disruption to Ca2+ homeostasis, oxidative stress, and mitochondrial dysfunction [5]. DMD patients
suffer severe limb and respiratory muscle weakness [6]. Patients have compromised lung function due
to diaphragm muscle weakness, altered chest wall compliance, and scoliosis [7]. Trans-diaphragmatic
pressures are low in DMD boys [8], and disordered breathing can occur, particularly during sleep,
leading to obstructive sleep apnea and hypoventilation [9]. Cardio-respiratory failure is the leading
cause of death in DMD.
Oxidative stress is the result of increased reactive oxygen species (ROS) and/or decreased
antioxidant capacity. ROS, in particular superoxide anions, are highly chemically reactive substances
that can react with nucleic acids, lipids, and proteins, thus hindering cellular metabolism, resulting
in cell injury [10]. Low levels of ROS are essential for optimal force production during muscle
contraction, and act as important physiological signaling molecules that alter enzymatic activity and
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gene expression [11]. Large amounts of ROS have deleterious effects on muscle force and endurance,
such as during strenuous exercise and chronic disease states, such as muscular dystrophy [12–14].
The most widely studied preclinical model of DMD is the dystrophin-deficient mdx mouse.
Diaphragm muscle from mdx mice displays similar characteristics to DMD patients, including
loss of function [15], muscle fibrosis and necrosis [16], inflammation, and oxidative stress [17].
Respiratory deficits are present in the mdx mouse, including hypoventilation [18]. An imbalance
between ROS production and antioxidant scavenging capacity in muscle can promote muscle damage
and mitochondrial dysfunction, with resultant impaired muscle function. Antioxidant capacity and
estimates of ROS turnover have been examined in a number of tissues from mdx mice, including
skeletal and cardiac muscle, and the brain. Markers of oxidative stress are increased in hearts from
mdx mice [19], as well as in limb and diaphragm muscle [20–22]. Increased superoxide dismutase
activity is reported in mdx cerebellum and prefrontal cortex, and this increase in antioxidant activity
was associated with decreased lipid peroxidation, suggesting a protective role of superoxide dismutase
in mdx mouse brain [23].
Disruption of the DAPC in DMD results in nitric oxide synthase (NOS) displacement from
the sarcolemma [3]. NOS has a physiological role in the synthesis of nitric oxide (NO), which
exerts protective effects in muscle in response to cell injury. Activity of the superoxide generating
enzyme complex nicotinamide adenine dinucleotide phosphate-oxidase (NOX) is increased in mdx
muscle [21,24]. Pharmacological inhibition of NOX, using apocynin, improved calcium handling
and contractility in mdx hearts [24]. Similarly, inhibition of ROS with diapocynin reduced ROS
production and prevented force loss induced by eccentric contractions in dystrophic limb muscle [25].
Increased ROS can activate pro-inflammatory pathways, resulting in inflammation and fibrosis, and
can promote Ca2+ dysregulation. Recent data suggest a complex interaction between oxidative stress,
Ca2+ dysregulation, and inflammation as secondary mediators of pathology in DMD [5,26,27].
Currently no cure exists for DMD, therefore, much work is focused on discovering novel therapies
for the treatment of the disease. In the present study, we used the mdx mouse model of DMD to
investigate the therapeutic potential of tempol on diaphragm muscle force and oxidative and glycolytic
metabolic enzyme activities. Tempol is a membrane permeable superoxide dismutase mimetic, which
exerts antioxidant effects by scavenging superoxide anions. Tempol acts by catalyzing the reaction of
superoxide into oxygen or hydrogen peroxide. Previous work has shown that tempol exerts a positive
inotropic effect on rat pharyngeal dilator muscle function ex vivo [28], and prevents hypoxia-induced
muscle weakness [29,30] and oxidative stress [31,32]. It is also established that tempol prevents
temperature-dependent force loss in mouse and rat muscle ex vivo [33]. We hypothesized that chronic
antioxidant therapy in mdx mice would improve diaphragm muscle function.
2. Materials and Methods
2.1. Ethical Approval
Procedures involving live animals were performed under license in accordance with Irish and
European legislation, following prior approval by University College Cork’s animal research ethics
committee. The approval number from University College Cork’s animal research ethics committee is
AEEC 2013/035.
2.2. Experimental Animals
Male and female wild-type (C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmdmdx/J) mice were
purchased from the Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME, USA) and bred
at University College Cork’s animal housing facility. Animals were housed conventionally in a
temperature- and humidity-controlled facility, operating on a 12 h light–12 h dark cycle with food and
water available ad libitum. Male mice were studied at 14 weeks of age, and were assigned to four
groups: wild-type (26.2 ± 1.6 g; n = 7), mdx (29.2 ± 2.8 g; n = 7), mdx + tempol in vitro (32.2 ± 2.5 g;
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n = 7) and mdx + tempol in vivo (30.1 ± 2.2g; n = 9); mdx animals were randomly assigned to groups.
The mdx + tempol in vivo group received tempol (1 mM 4-hydroxy-TEMPO; Sigma Aldrich, Wicklow,
Ireland) in their drinking water for two weeks (from 12 to 14 weeks of age), equivalent to a dose of
20–35 mg/g body weight, taking an estimate of fluid intake and known body mass gain over the
intervention period. The dose was informed by previously published work in rat, wherein tempol
proved efficacious in preventing respiratory muscle dysfunction in response to redox stress associated
with exposure to chronic intermittent hypoxia [29,30].
2.3. Muscle Physiology
2.3.1. Ex Vivo Muscle Preparation
Animals were anaesthetized with 5% isoflurane in air, and euthanized by cervical dislocation.
Diaphragm muscle was immediately excised, with central tendon and rib intact for functional studies.
Additional diaphragm muscle samples were snap frozen in liquid nitrogen and stored at −80 ◦C for
later analysis. Diaphragm muscle was suspended vertically in a water-jacketed tissue bath at 35 ◦C,
filled with Krebs solution (in mM: 120 NaCl, 5 KCl, 2.5 Ca2+ gluconate, 1.2 MgSO4, 1.2 NaH2PO4,
25 NaHCO3 and 11.5 glucose) and D-tubocurarine (25 µM). Preparations were equilibrated with
hyperoxic (95% O2/5% CO2) gas. The rib end of the preparation was attached to an immobile hook
at the base of a muscle holder, and the central tendon was attached to a dual mode lever transducer
system (Aurora Scientific Inc., Aurora, ON, Canada) with non-elastic string, to allow the assessment of
isometric and isotonic contractile properties. For the mdx + tempol in vitro group, diaphragm muscle
from mdx mice was studied in Krebs solution containing 1 mM tempol, which has been shown to exert
positive inotropic effects on rat respiratory muscle in isolated muscle preparations [28,29]).
2.3.2. Isometric Protocol
The muscle strips were stimulated via field stimulation with platinum electrodes at supramaximal
voltage. Optimal length (Lo), the length producing maximum twitch force, was obtained by repeated
isometric twitch stimulation (supramaximal voltage; 1 ms duration) at varying muscle lengths,
achieved by adjustment of a micro-positioner. The Lo was recorded, and the muscle remained at
this length for the remainder of the experiment. Following a 10 min equilibration period, contractile
properties were examined. First, a single twitch was elicited, and twitch force, contraction time (CT;
time to peak force), and half-relaxation time ( 12 RT; time for force to decay by 50%) were determined.
Next, an isometric tetanic contraction was elicited by stimulating muscle strips with supramaximal
voltage at 100 Hz for 300 ms duration. Peak isometric tetanic force (Fmax) was determined [34,35].
2.3.3. Isotonic Protocol
Concentric contractions were evoked at varying loads in an incremental step-test (0%, 5%, 10%,
20%, 30%, 40%, 50%, 60%, 80%, 100%; % of Fmax). Each contraction was interspaced by 1 min,
and muscle length returned to Lo following each contraction. Total shortening was considered the
maximum distance shortened during contraction; shortening velocity was measured during the initial
30 ms of shortening [34,36]. Mechanical work (force x total shortening) and power (force x shortening
velocity) were measured at each % load [34,37].
2.4. Muscle Biochemistry
2.4.1. Tissue Preparation
Diaphragm samples stored at −80 ◦C were removed and allowed to defrost at 4 ◦C for 5 min. All
procedures were performed at 4 ◦C to prevent protein degradation. Samples were homogenized in
a lysis buffer (RIPA) made up from 10× RIPA, deionized water, 200 mM sodium fluoride, 100 mM
phenylmethylsulfonyl fluoride, protease cocktail inhibitor 1, and phosphatase cocktail inhibitor 2.
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Following the homogenization process, the reactant mixtures were centrifuged (15,339× g) and the
supernatants were harvested. Total amount of protein for each tissue sample was determined using
Pierce® Bicinchoninic Acid Assay (BCA assay, Thermo Scientific, Fisher, Dublin, Ireland). Supernatants
were aliquoted and stored at −80 ◦C for future use.
2.4.2. Metabolic Enzyme Assays
Tissue homogenates were used for enzymatic activity assays. The experimental procedures for
citrate synthase, phosphofructokinase, and lactate dehydrogenase activity assays were performed in
accordance with the technical bulletins of a citrate synthase assay kit (CS0720; Sigma-Aldrich, Wicklow,
Ireland), phosphofructokinase activity colorimetric assay kit (MAK093; Sigma-Aldrich), and lactate
dehydrogenase activity assay kit (MAK066; Sigma-Aldrich), respectively. Results are presented as
enzymatic activity per 1 mg of protein in tissue homogenate.
2.5. Data Analysis
Specific force was normalized for muscle tissue cross-sectional area (CSA), and calculated in
N/cm2. Muscle CSA was estimated for each muscle strip by dividing the muscle mass (weight in
grams) by the product of muscle Lo (cm) and muscle density (assumed to be 1.06 g/cm3). For isotonic
load relationships, data were expressed as the measured parameter versus % load. Total muscle
shortening was normalized to Lo and expressed in Lo/s. Maximal total shortening (Smax) and
maximum shortening velocity (Vmax) occurred at 0% load. Maximum mechanical work (Wmax)
and power (Pmax) occurred at ~30–40% load.
2.6. Statistical Analysis
Values are expressed as mean ± SD or are represented graphically as box and whisker plots
(median, 25th–75th centile, and minimum and maximum). Data were statistically compared by
unpaired Student’s t tests with Welch’s correction where appropriate, and two-way analysis of variance
(ANOVA); for data from incremental load tests). p < 0.05 was deemed to be statistically significant.
3. Results
3.1. Isometric Force and Twitch Contractile Kinetics
Representative original traces for diaphragm muscle twitch (A) and tetanic (B) contractions and
maximum unloaded shortening (C) are shown in Figure 1 for wild-type, mdx, mdx + tempol in vitro
and mdx + tempol in vivo. Table 1 shows data for diaphragm muscle twitch force and contractile
kinetics from all four groups. Twitch force was significantly lower in mdx compared with wild-type
diaphragm (p = 0.0066, Student’s t test). There was a significant decrease in diaphragm 12 RT following
tempol administration in vivo in mdx mice (p = 0.0046). Twitch force was significantly higher in mdx
+ tempol in vivo compared with mdx (p = 0.0111). Fmax was significantly lower in mdx diaphragm
compared with wild-type (p < 0.0001; Figure 1D). Fmax was significantly higher in mdx + tempol,
in vivo, compared with mdx (p = 0.0069), such that values were equivalent to wild-type values for
peak force generation. Bath application of tempol to mdx diaphragm had no effect on force-generating
capacity or contractile kinetics compared with mdx (Figure 1 and Table 1).
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the mdx + tempol in vitro group, diaphragm muscle preparations were studied in Krebs solution 
containing 1 mM tempol in vitro. The mdx + tempol in vivo group received 1 mM tempol in their 
drinking water for two weeks. Values are expressed as box and whisker plots (median, 25–75% 
centiles and minimum and maximum values) and data were statistically compared by Student’s t 
tests. *** p < 0.0001; ** p = 0.0069. 
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Figure 1. Peak Isometric Tetanic Force. Representative traces for muscle twitch (A) and tetanic (B)
contractions and maximum unloaded shortening (C) for diaphragm muscle from wild-type, mdx, mdx +
te pol in vitro and dx + te pol in vivo. Group data for diaphragm muscle peak tetanic force (D) from
wild-type (n = 7), mdx (n = 7), mdx + tempol in vitro (n = 7) and mdx + tempol in vivo (n = 8). For the
mdx + tempol in vitro group, diaphragm muscle preparations were studied in Krebs solution c ntaining
1 mM tempol in vitro. The mdx + tempol in vivo gr up received 1 mM tempol in their drinking water for
two weeks. Values are expressed s box and whisker plots (median, 25–75% centiles an minimum and
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Table 1. Diaphragm Muscle Contractile Properties.
Wild-Type (n = 7) Mdx (n = 7) mdx + TempolIn Vitro (n = 7)
mdx + Tempol
In Vivo (n = 8) Student’s t Test
CT (ms) 18.0 ± 1.8 20.5 ± 4.5 17.9 ± 1.5 20.2 ± 3.1 $: p = 0.2196; †: p = 0.1796; £: p = 0.8777
1
2 RT (ms) 23.5 ± 0.6 23.5 ± 0.5 23.2 ± 0.2 17.8 ± 3.9 $: p = 0.9803; †: p = 0.1197; £: p = 0.0046
Pt (N/cm2) 5.1 ± 1.7 2.5 ± 0.7 2.7 ± 0.7 4.0 ± 1.2 $: p = 0.0066; †: p = 0.4821; £: p 0.0111
Wmax (J/cm2) 1.3 ± 0.5 0.7 ± 0.2 0.7 ± 0.4 1.5 ± 0.7 $: p = 0.0276; †: p = 0.6852; £: p = 0.0085
Pmax (W/cm2) 9.0 ± 3.8 5.8 ± 0.9 4.7 ± 1.6 11.0 ± 4.9 $: p = 0.0709; †: p = 0.1329; £: p = 0.0217
Smax (L/Lo) 0.32 ± 0.06 0.28 ± 0.07 0.24 ± 0.03 0.34 ± 0.10 $: p = 0.3457; †: p = 0.1532; £: p 0.1936
Vmax (Lo/s) 3.5 ± 1.3 3.8 ± 0.8 2.7 ± 0.9 4.5 ± 2.0 $: p = 0.6766; †: p = 0.0353; £: p = 0.3433
Values (mean ± SD) for twitch contraction time (CT), twitch half-relaxation time ( 12 RT), peak twitch force (Pt),
maximum mechanical work (Wmax), maximum mechanical power (Pmax), peak shortening (Smax), and eak
shortening velocity (Vmax) of diaphragm muscle from the following groups: wild-type (n = 7), mdx (n = 7),
mdx + tempol in vitro (n = 7) and mdx + tempol in vivo (n = 8). For the mdx + tempol in vitro group, diaphragm
muscle preparations were studied in Krebs solution containing 1 mM tempol in vitro. The mdx + tempol in vivo
group received 1 mM tempol in their drinking water for two weeks. Data were statistically compared by unpaired
Student’s t tests with Welch’s correction where appropriate. $: Wild-Type vs. mdx; †: mdx vs. mdx Tempol in vitro;
£: mdx vs. mdx Tempol in vivo.
3.2. Isotonic Contractile Parameters and Kinetics
Table 1 shows data for diaphragm muscle isotonic contractile parameters. Wmax was significantly
lower in mdx compared with wild type diaphragm (p = 0.0276; Student t test). Wmax was significantly
elevated in mdx + tempol in vivo compared with mdx (p = 0.0085). Pmax was lower in mdx diaphragm
compared with wild-type, but this did not reach statistical significance (p = 0.0709). Pmax was
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significantly elevated in mdx + tempol in vivo compared with mdx (p = 0.0217), completely restoring
Pmax to wild-type values. No significant differences were noted for Smax between groups. Bath
application of tempol to mdx diaphragm significantly decreased Vmax compared with mdx (p = 0.0353),
but had no effect on Wmax or Pmax.
3.3. Isotonic Load Relationships
Figure 2A–D shows data for diaphragm muscle isotonic load relationships. Loading had a
significant effect on work (p < 0.0001; two-way ANOVA; Figure 2A), power (p < 0.0001; Figure 2B),
shortening (p < 0.0001; Figure 2C) and shortening velocity (p < 0.0001; Figure 2D) for diaphragm
muscle from all four groups. Work (p = 0.0071) and power production (p = 0.0115) were significantly
reduced in mdx diaphragm compared with wild-type. Tempol supplementation in vivo in mdx mice
significantly increased work (p = 0.0063) and power (p = 0.0177) production compared with mdx.
Bath application of tempol significantly reduced mdx diaphragm power production (p = 0.0037) and
shortening velocity (p = 0.0159) compared with mdx.
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power—(B), shortening—(C) and shortening velocity—(D) load relationships for diaphragm muscle 
from wild-type (n = 7), mdx (n = 7), mdx + tempol in vitro (n = 7) and mdx + tempol in vivo (n = 8). For 
the mdx + tempol in vitro group, diaphragm muscle preparations were studied in Krebs solution 
containing 1 mM tempol in vitro. The mdx + tempol in vivo group received 1 mM tempol in their 
Figure 2. Diaphragm Muscle Isotonic Contractile Properties. Group data (mean ± SD) for work—(A),
power—(B), shortening—(C) and shortening velocity—(D) load relationships for diaphragm muscle
from wild-type (n = 7), mdx (n = 7), mdx + tempol in vitro (n = 7) and mdx + tempol in vivo (n = 8). For the
mdx + tempol in vitro group, diaphrag muscle preparations were studied in Krebs solution containing
1 mM tempol in vitro. The mdx + tempol in vivo group received 1 mM tempol in their drinking water
for two weeks. Data were statistically compared by two-way analysis of variance (ANOVA). Work:
Load: p < 0.0001; Gene: p = 0.0071; tempol in vitro: p = 0.5020; tempol in vivo: p = 0.0063; Power: Load:
p < 0.0001; Gene: p = 0.0115; tempol in vitro: p = 0.0037; tempol in vivo: p = 0.0177; Shortening: Load:
p < 0.0001; Gene: p = 0.7068; tempol in vitro: p = 0.0995; tempol in vivo: p = 0.1117; Velocity: Load:
p < 0.0001; Gene: p = 0.1756; tempol in vitro: p = 0.0159; tempol in vivo: p = 0.5427.
3.4. Metabolic Enzyme Activity
Figure 3A–C shows data for diaphragm muscle metabolic enzyme activities. Citrate synthase
activity was significantly lower in mdx diaphragm compared with wild-type (p = 0.0003; unpaired
Student’s t test; Figure 3A). Chronic tempol supplementation in mdx significantly increased diaphragm
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citrate synthase activity compared with mdx (p = 0.005). No significant differences were noted between
groups for diaphragm phosphofructokinase activity (Figure 3B).
Lactate dehydrogenase activity was significantly lower in mdx diaphragm compared with
wild-type (p = 0.001; Figure 3C). Chronic tempol supplementation in mdx significantly increased
diaphragm lactate dehydrogenase activity compared with mdx (p = 0.0018).
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Figure 3. Metabolic Enzyme Activities. Group data for citrate synthase (A), phosphofructokinase
(B), and lactate dehydrogenase (C) enzyme activities in diaphragm muscle from wild-type, mdx and
mdx + tempol in vivo. mdx + tempol in vivo received 1 mM tempol in their drinking water for two
weeks. Values are expressed as box and whisker plots (median, 25–75% centiles and minimum and
maximum values), and data were statistically compared by unpaired Student’s t tests. (A) *** p = 0.0003;
** p = 0.005. (C) *** p = 0.001; ** p = 0.0018.
Antioxidants 2017, 6, 101 8 of 16
4. Discussion
The main findings of this study are (1) diaphragm muscle weakness in mdx mice is evidenced
by reduced specific force, work and power output; (2) dystrophin-deficiency in mdx diaphragm
is associated with reduced citrate synthase and lactate dehydrogenase enzyme activities, whereas
phosphofructokinase activity is equivalent to wild-type; (3) chronic tempol supplementation in
mdx mice completely restored diaphragm force- and power-generating capacity; (4) chronic tempol
supplementation significantly increased mdx diaphragm citrate synthase and lactate dehydrogenase
enzyme activities to wild-type levels; (5) acute bath application of tempol had limited effects on
dystrophic diaphragm function ex vivo.
Diaphragm muscle thickening and fat accumulation are described in DMD patients, associated
with diaphragm muscle weakness [38,39]. Ventilatory capacity decreases with age, since DMD is a
progressive disease [8,40]. Respiratory failure is a leading cause of mortality in DMD. Although DMD
is primarily caused by a genetic abnormality resulting in the absence of the dystrophin protein, many
secondary pathologies have been identified as contributing to the muscle pathology observed in DMD,
including inflammation, Ca2+ dysregulation, and redox stress [5,26].
Diaphragm muscle degeneration, fibrosis, and dysfunction are reported in mdx mice, which
display an overt pathology similar to human DMD [16]. In the present study, we report diaphragm
weakness in mdx mice consistent with other reports [15,16,41]. Diaphragm weakness in mdx was
characterized by reduced twitch and tetanic muscle force and reduced Wmax. Diaphragm muscle
mechanical work and power generation were reduced across the load continuum, revealing severe
intrinsic mechanical dysfunction in dystrophic diaphragm muscle. These functional deficits were
associated with altered metabolic enzyme activities, characterized by reduced citrate synthase and
lactate dehydrogenase activity. Citrate synthase catalyzes the first step within the Krebs cycle,
the condensation of acetyl-coenzyme A with oxaloacetate to form citrate, and serves as a marker
of the mitochondrial matrix. Reduced citrate synthase activity suggests reduced mitochondrial
activity, and hence, aerobic capacity in mdx diaphragm. This reduction in mitochondrial activity
may relate to a loss of mitochondrial content, resulting in reduced oxidative capacity, or may be due
to oxidative stress-induced mitochondrial dysfunction or mitophagy. Phosphofructokinase catalyzes
the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate, thus functioning as a key
regulatory step in the glycolytic pathway. Phosphofructokinase activity was unchanged in mdx
diaphragm compared with wild-type. Lactate dehydrogenase catalyzes the forward and backward
conversion of pyruvate to lactate, with the skeletal muscle isoform kinetically favoring conversion
from pyruvate to lactate. Since glycolysis, which diverts pyruvate to lactate, serves to diminish redox
stress [42], reductions in lactate dehydrogenase activity can cause oxidative stress associated with
increased cellular oxygen consumption [43]. Metabolic reprogramming in mdx and DMD muscle is
complex, and likely temporally regulated in dynamic fashion. Indeed, contrary to our observation,
a recent report revealed elevated activity in oxidative enzymes of the Krebs cycle in mdx diaphragm [44].
Indicators of oxidative stress, such as 4-hydroxynonenal (4-HNE) and dihydroethdium (DHE),
are increased in mdx diaphragm, revealing increased oxidative stress which likely has functional
implications [17]. Antioxidant enzymes, such as superoxide dismutase, catalase and glutathione
peroxidase, are elevated in limb muscle from mdx mice [20], which may contribute to the mild limb
muscle phenotype which is observed in mdx mice compared with the diaphragm muscle, which more
closely represents the human diaphragm pathology. Studies have shown that NOX subunits and
superoxide production are increased in skeletal muscle of mdx mice [21,45]. Oxidative stress contributes
to cardiomyocyte dysfunction in dystrophic hearts, and NOX2 inhibition resulted in restoration
of calcium handling and contractility, and reduced collagen expression in cardiomyocytes [19,24].
The NOX subunits gp91phox, p67phox and Rac1 are increased in the tibialis anterior of mdx mice,
associated with increased superoxide production [21].
Tempol has previously been shown to have positive inotropic effects on rat pharyngeal dilator
(respiratory) muscle performance ex vivo [28,29]. Interestingly, tempol was shown to ameliorate upper
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airway muscle weakness in a rat model of chronic intermittent hypoxia [29]. In a similar model of
chronic intermittent hypoxia, tempol exerted modest effects on diaphragm muscle force, but reversed
chronic intermittent hypoxia-induced diaphragm fatigue [30]. Chronic tempol supplementation has
also been shown to prevent sustained hypoxia induced pharyngeal dilator muscle weakness [31],
but not diaphragm muscle dysfunction [37]. Collectively, these studies illustrate that tempol can
exert inotropic effects on rodent respiratory muscle and ameliorate muscle weakness in models of
hypoxic stress via superoxide scavenging, although this capacity appears muscle specific and may
be dependent on the mode of hypoxia (sustained versus intermittent). This may have relevance to
putative hypoxia-dependent remodeling in mdx muscle. DMD patients [9,46] and mdx mice [47,48]
hypoventilate. DMD patients exhibit nocturnal hypoxemia and sleep-disordered breathing [49,50],
and exposure to chronic intermittent hypoxia has been shown to further weaken mdx diaphragm [51].
Therefore, hypoxic stress may be implicated in mdx and DMD pathology, such that antioxidant
strategies (such as tempol), proven to prevent hypoxia-dependent respiratory muscle weakness and
fatigue, may be especially useful.
Since elevated superoxide production is reported in the diaphragm muscle of mdx mice, we sought
to examine the efficacy of the superoxide scavenger tempol on mdx diaphragm muscle function. To our
knowledge, this is the first report on the effects of tempol on muscle function and metabolic enzyme
activity in the mdx mouse. Chronic tempol supplementation resulted in increased diaphragm force
generation, revealed both in twitch and tetanic contractions, impressively restoring these functional
indices to values equivalent to wild-type values. Work- and power-generating capacity expressed as a
function of load were significantly increased in diaphragm from tempol supplemented mice compared
with mdx, resulting in a complete restoration of work- and power-generating capacity. Wmax and
Pmax were similarly significantly increased. Interestingly, tempol decreased 12 RT for mdx diaphragm,
suggesting an increased rate of calcium reuptake into the sarcoplasmic reticulum during muscle
relaxation. These functional improvements in mdx diaphragm are likely attributable to scavenging of
excessive ROS in mdx diaphragm [17,21,45], and improvements in calcium handling.
In the current study, the finding that acute bath application of tempol significantly reduced mdx
diaphragm Vmax, demonstrates the functional significance of ROS signaling, most likely superoxide,
within mdx diaphragm muscle preparations. Basal ROS are known to have physiological roles in
cross-bridge cycling and muscle force generation [11]. However, elevated levels of ROS orchestrate
a pro-oxidant environment, which can serve to impair cross-bridge cycling, and thus, reduce
force production. A tonic inhibitory effect of ROS on respiratory muscle function, suppressing
force-generating capacity, was revealed by the observation of positive inotropic effects of acute bath
application of the superoxide scavengers, tempol, and tiron [28]. Moreover, H2O2 has been shown
to cause concentration-dependent inotropic effects on rat respiratory muscle function, with high
concentrations of ROS resulting in muscle weakness and fatigue, an effect blocked by catalase [52].
Notwithstanding the capacity for antioxidant scavenging to acutely affect muscle performance,
the general lack of effect of bath application of tempol in mdx diaphragm is not surprising. We posit
that chronically elevated levels of ROS in mdx diaphragm induce structural abnormalities that cannot
be reversed by acute tempol application. Rather, it is evident that chronic antioxidant supplementation
is required to re-establish redox homeostasis, returning ROS to physiological levels, limiting redox
stress, allowing restoration of muscle function. The functional improvements in mdx diaphragm
extended to restoration of citrate synthase and lactate dehydrogenase enzyme activities. Improved
metabolic enzyme activity has obvious consequences for improved mdx diaphragm performance.
We used enzyme activity as a surrogate marker for oxidative stress, since these proteins are often
targets of redox stress, and can in turn be drivers of redox stress owing to alterations in bioenergetics.
We interpret the restoration of aerobic and glycolytic enzyme activities as indirect evidence of the
efficacy of tempol in ameliorating oxidative stress in mdx diaphragm, with the important added benefit
of restoring energy homeostasis and ATP-generating capacity.
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Previously, EUK-134, a novel catalytic mimetic of superoxide dismutase and catalase, was used
to examine the role of oxidative stress in mdx diaphragm pathology. EUK-134 reduced markers of
oxidative stress, inflammation, and indicators of muscle damage in mdx diaphragm, although only
a partial rescue of diaphragm force was observed [53]. Treatment of mdx mice with ascorbic acid,
an antioxidant and free radical scavenger, was shown to reduce creatine kinase levels, myonecrosis,
inflammation, and the levels of 4-HNE [54]. These studies further highlight the close relationship
between ROS and inflammation in dystrophic diaphragm. Beyond antioxidant effects, targeting ROS
using antioxidant interventions in mdx mice may also have non-specific anti-inflammatory actions,
further supporting their use as a potential therapeutic strategy in DMD. In respect of interventional
studies in DMD, our data suggest that superoxide scavengers warrant attention. Tempol is not
approved for use in humans, but dietary and/or pharmacotherapies mimicking its actions could prove
beneficial in DMD. Many studies have revealed beneficial effects of antioxidants on muscle integrity
(Table 2), but few studies have assessed the effects of antioxidants on diaphragm force generating
capacity. It will be interesting to determine how tempol compares to previous studies in respect of
improvements in diaphragm structure and quality.
The current study has relevance to therapeutic interventions in DMD, particularly those aimed
at alleviating respiratory deficits in DMD boys. Since diaphragmatic weakness is observed in DMD
boys, and likely contributes to breathing disturbances and the development of respiratory failure,
strategies aimed at improving diaphragm muscle functional capacity in DMD are attractive. In respect
of the current data set, it would be interesting in future studies to examine the effects of tempol
supplementation on respiratory and cardiac function in mdx mice.
Limitations
We acknowledge the current study employed a single dose of tempol at one time point in a
progressive disease. However, notably, our intervention resulted in full recovery of diaphragm
force. Future research should examine dose-dependent effects of tempol in mdx mice on respiratory
and non-respiratory muscle structure and function. Mitochondrial function and direct measures of
oxidative stress should be examined to determine the mechanism of force recovery in mdx diaphragm
following tempol supplementation.
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Table 2. Overview of studies assessing antioxidant intervention in mdx mice.
Antioxidant Author Classification Model Age Dose/Method of Delivery Tissue Examined Results
α-lipoic
acid/L-carnitine
Hnia K. et al.,
2007 [55]
Free radical
scavenger mdx mouse 5 weeks old
250 mg/kg α-lipoic
acid/L-carnitine i.p injection
for 14 days
Diaphragm
α-lipoic acid/L-carnitine decreased plasma CK levels and decreased
muscle fibre central nucleation and fibre variance, antioxidant activity,
lipid peroxidation, NF-kB and matrix metalloproteinase activity in mdx
diaphragm. B-dystroglycan expression was increased in mdx diaphragm
following α-lipoic acid/L-carnitine.
Apocynin Gonzalez D.R.et al., 2014 [24]
NADPH oxidase
inhibitor
mdx cardiac
myocytes - 100 µM apocynin in vitro
Isolated cardiac
myocytes
Apocynin restored contractility in mdx cardiac myocytes and normalised
the amplitude of evoked intracellular Ca2+ concentration transients and
total SR Ca2+ content. The production of spontaneous diastolic Ca2+
release events was decreased and SR Ca2+ leakage was decreased,
thus apocynin improved SR Ca2+ handling and
contractility in mdx cardiac myocytes.
Ascorbic acid
(vitamin C)
Tonon E. et al.,
2012 [54] Antioxidant mdx mouse 14 days old
Ascorbic acid 200 mg/kg via
oral gavage daily for 14 days Diaphragm
Ascorbic acid decreased plasma CK levels and diaphragm myonecrosis,
inflammation, TNF-α and 4-HNE levels and Evans
blue dye staining in mdx mice.
Cilostazol Hermes Tde A.E. et al.,2016 [56] PDE3 inhibitor mdx mouse 14 days old
Cilostazol 100 mg/kg/day
for 14 days Diaphragm
Cilostazol reduced plasma CK and diaphragm myonecrosis, inflammatory
cell area and macrophage infiltration, NF-kB and TNF-α content,
ROS production and oxidative stress in mdx mice.
Diacerhein Mâncio R.D. et al.,2017 [57] IL-1β inhibitor mdx mouse 14 days old
20 mg/kg/day diacerhein via
oral gavage for 14 days Diaphragm
Diacerhin reduced plasma CK levels, diaphragm muscle fibre damage and
central nucleation, inflammatory mediators, oxidative
stress and lipid peroxidation in mdx mice.
EUK-134 Kim J.H. and LawlerJ.M. 2012 [53]
Superoxide
dismutase mimetic mdx mouse 20 days old
30 mg/kg/day EUK-134 i.p.
injection for 8 days Diaphragm
EUK-134 reduced 4-HNE, total hydroperoxides, positive staining of
macrophages and T-cells, activation of NF-κB, p65 protein abundance and
the number of centralised myonuclei and variability of fibre size in
diaphragm muscle from mdx mice. Diaphragm contractile force was
partially rescued following EUK-134 and increased
citrate synthase activity in mdx mice.
Epigallocatechin-3-
gallate (EGCG)
Nakae Y. et al.,
2008 [58]
Green tea
extract/antioxidant/
Polyphenol
mdx mouse From birth 5 mg/kg EGCG s.c. injection4 times per week for 8 weeks Diaphragm
EGCG had no effect on body weight and no observable toxic effects in the
liver and kidney. EGCG decreased plasma CK and decreased the number
of lipofuscin granules, necrotic muscle fibres and connective tissue in mdx
diaphragm and increased utrophin expression.
EGCG did not affect diaphragm isometric force.
SNT-NC17/Idebenone Buyse G.M. et al.,2009 [59] Antioxidant mdx mouse 4 weeks old
200 mg/kg
SNT-MC17/idebenone
for 9 months
Heart
SNT-NC17/Idebenone corrected cardiac diastolic dysfunction, improved
contractile reserve and voluntary running and decreased cardiac
inflammation and fibrosis in mdx mice.
L-arginine Marques M.J. et al.,2010 [60] Amino acid mdx mouse 6 months old
L-arginine in drinking water
for 6 months Heart
L-arginine had no effect on myocardial fibrosis but reduced the density of
inflammatory cells in the mdx heart.
N-acetylcysteine
(NAC)
Williams I.A. and
Allen D.G. 2007 [19]
Glutathione
precursor mdx mouse 3 weeks old
1% NAC in drinking water
for 6 weeks Heart
NAC reduced DHE levels in mdx hearts, reduced abnormalities in mdx
cardiomyocyte Ca2+ handling, returned mdx fractional shortening to WT
values but did not affect Ca2+ sensitivity. NAC returned collagen type III
and CD68 expression in mdx hearts to WT values.
N-acetylcysteine
(NAC)
de Senzi Moraes Pinto
R. et al., 2013 [61]
Glutathione
precursor mdx mouse 14 days old
150 mg/kg NAC i.p.
daily for 14 days Diaphragm
NAC reduced plasma CK levels and reduced TNF-α and 4-HNE protein
adduct levels, inflammation, Evans blue dye staining and
myonecrosis in mdx diaphragm muscle.
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Table 2. Cont.
Antioxidant Author Classification Model Age Dose/Method of Delivery Tissue Examined Results
Resveratrol Kuno A. et al.,2013 [62] SIRT1 activator mdx mouse 9 weeks old
4 g/kg resveratrol enriched
diet for 32 weeks Heart
Resveratrol downregulated the pro-hypertrophic co-activator p300 protein
level in the mdx heart thus inhibiting fibre hypertrophy. Resveratrol also
suppressed cardiac fibrosis and preserved
cardiac diastolic function in mdx hearts.
Pentoxifylline Gosselin L.E. andWilliams J.E. 2006 [63] PDE inhibitor mdx mouse 4 weeks old
16 mg/kg/day
pentoxyifylline for 4 weeks Diaphragm
Pentoxyifylline had no effect on mdx diaphragm force, hydroxyproline
concentration, type I and III procollagen mRNA and TGF-β mRNA.
Pentoxifylline Burdi R. et al.,2009 [64] PDE inhibitor mdx mouse 4–5 weeks old
50 mg/kg/day
pentoxyifylline i.p. injection
for 4–8 weeks
Diaphragm Pentoxifylline modestly increased mdx diaphragm isometric tetanic force.
Pyrrolidine
dithiocarbamate
(PDTC) or
ursodeoxycholic
acid(UDCA)
Graham K.M. et al.,
2010 [65] NF-κB inhibitors mdx mouse 30 days old
50 mg/kg/day PDTC i.p.
injection for one month
40 mg/kg/day UDCA i.p.
injection for one month
Diaphragm Neither PDTC or UDCA influenced collagen deposition or TGF-β1expression in mdx diaphragm.
Quercetin Hollinger K. et al.,2015 [66]
PGC-1α pathway
activator mdx mouse 3 months old
0.2% quercetin-enriched diet
for 6 months Diaphragm
Quercetin preserved diaphragm muscle fibres and reduced centralised
nuclei, infiltrating immune cells, TNF-α gene expression and muscle
fibrosis in mdx mice. Genes associated with oxidative
metabolism were increased following quercetin.
Quercetin Selsby J.T. et al.,2016 [67]
PGC-1α pathway
activator mdx mouse 2 months old
0.2% quercetin-enriched diet
for 12 months Diaphragm
Quercetin protected respiratory function in mdx mice during the first 4–6
months and declined thereafter. Mdx diaphragm muscle function and
histology were not preserved following 12 months of quercetin treatment.
Quercetin Ballmann C. et al.,2017 [68]
PGC-1α pathway
activator mdx mouse 2 months old
0.2% quercetin-enriched diet
for 12 months Heart
Quercetin decreased fibronectin, inflammation and indices of tissue
damage while mitochondrial biogenesis and antioxidant enzymes were
improved, and quercetin facilitated
the assembly of the DAPC in mdx hearts.
Quercetin Ballmann C. et al.,2015 [69]
PGC-1α pathway
activator mdx mouse
3 weeks old
3 months old
0.2% quercetin-enriched diet
for 6 months Heart
3 weeks old: Quercetin increased cytochrome-c and superoxide dismutase
2 protein expression, increased utrophin and decreased matrix
metalloproteinase 9 abundance in mdx heart.
3 months old: Quercetin decreased relative and absolute heart weights,
damage indicators and TGFβ-1 in mdx heart.
Sildenafil Percival J.M. et al.,2012 [70] PDE-5 inhibitor mdx mouse 3 weeks old
400 mg/L sildenafil citrate in
drinking water for 14 weeks Diaphragm
Sildenafil modestly increased diaphragm force generating capacity and
reduced fibronectin, TNF-α, matrix metalloproteinase 13 and Evans blue
dye staining in the mdx diaphragm.
Fatigue resistance and TGF-β were unaffected.
Vitamin E Mancio R.D. et al.,2017 [71]
Peroxyl radical
scavenger mdx mouse 14 day old
40 mg vitamin E/kg daily via
oral gavage for 14 days Diaphragm
Vitamin E reduced muscle fibre damage, oxidative stress and
inflammation processes in mdx diaphragm.
List of abbreviations: 4-HNE, 4-Hydroxynonenal; Ca2+, calcium; CD68, cluster of differentiation 68; CK, creatine kinase; DHE, dihydroethidium; EGCG, epigallocatechin-3-gallate; IL-1β,
interleukin-1 beta; i.p., intra-peritoneal; MMP, matrix metalloproteinase; NAC, N-acetylcysteine; NADPH, nicotinamide adenine dinucleotide phosphate-oxidase; NFκB, nuclear factor
lappa-light-chain-enhancer of activated B cells; PDE, phosphodiesterase; PDTC, pyrrolidine dithiocarbamate; PGC-1α, peroxisome proliferator activated receptor gamma co-activator
1 alpha; ROS, reactive oxygen species; SR, sarcoplasmic reticulum; s.c., sub-cutaneous; SIRT-1, sirtuin-1;TGF-β1, tumour growth factor beta 1; TNF-α, tumour necrosis factor alpha; UDCA,
ursodeoxycholic acid.
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5. Conclusions
In conclusion, our findings show that tempol supplementation in mdx mice is efficacious,
serving to restore diaphragm force- and power-generating capacity to levels equivalent to wild-type
values. Functional improvements were accompanied by restoration of citrate synthase and lactate
dehydrogenase enzyme activities in mdx diaphragm. Our study implicates superoxide anions and
downstream ROS as pivotal mediators of dystrophin-deficient respiratory muscle pathophysiology.
Recovery of diaphragm muscle contractile function was impressive in our study highlighting the
potential utility of tempol and other superoxide scavengers in the treatment of DMD.
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